| Nanoparticles and targeted drug delivery in cancer therapy B Bahrami, M Hojjat-Farsangi, H Mohammadi, E Anvari, G Ghalamfarsa, ... Immunology letters 190, 64-83, 2017 | 581 | 2017 |
| The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer A Masjedi, V Hashemi, M Hojjat-Farsangi, G Ghalamfarsa, G Azizi, ... Biomedicine & Pharmacotherapy 108, 1415-1424, 2018 | 296 | 2018 |
| Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies M Hojjat-Farsangi International journal of molecular sciences 15 (8), 13768-13801, 2014 | 279 | 2014 |
| CD73 as a potential opportunity for cancer immunotherapy G Ghalamfarsa, MH Kazemi, S Raoofi Mohseni, A Masjedi, ... Expert opinion on therapeutic targets 23 (2), 127-142, 2019 | 148 | 2019 |
| Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer MH Kazemi, S Raoofi Mohseni, M Hojjat‐Farsangi, E Anvari, ... Journal of Cellular Physiology 233 (3), 2032-2057, 2018 | 147 | 2018 |
| Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells AH Daneshmanesh, M Hojjat-Farsangi, AS Khan, M Jeddi-Tehrani, ... Leukemia 26 (6), 1348-1355, 2012 | 138 | 2012 |
| Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy B Bahrami, M Mohammadnia-Afrouzi, P Bakhshaei, Y Yazdani, ... Tumor Biology 36, 5727-5742, 2015 | 136 | 2015 |
| The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia S Eghbal‐Fard, M Yousefi, H Heydarlou, M Ahmadi, S Taghavi, ... Journal of cellular physiology 234 (4), 5106-5116, 2019 | 135 | 2019 |
| Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer V Karpisheh, A Nikkhoo, M Hojjat-Farsangi, A Namdar, G Azizi, ... Prostaglandins & other lipid mediators 144, 106338, 2019 | 117 | 2019 |
| The receptor tyrosine kinase ROR1–an oncofetal antigen for targeted cancer therapy M Hojjat-Farsangi, A Moshfegh, AH Daneshmanesh, AS Khan, ... Seminars in cancer biology 29, 21-31, 2014 | 116 | 2014 |
| Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies AH Daneshmanesh, A Porwit, M Hojjat-Farsangi, M Jeddi-Tehrani, ... Leukemia & lymphoma 54 (4), 843-850, 2013 | 105 | 2013 |
| CDK1 in breast cancer: implications for theranostic potential S Izadi, A Nikkhoo, M Hojjat-Farsangi, A Namdar, G Azizi, H Mohammadi, ... Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents) 20 (7), 758-767, 2020 | 97 | 2020 |
| Quantum dots as targeted doxorubicin drug delivery nanosystems in human lung cancer cells M Ruzycka-Ayoush, P Kowalik, A Kowalczyk, P Bujak, AM Nowicka, ... Cancer Nanotechnology 12, 1-27, 2021 | 91 | 2021 |
| Mechanisms of tumor cell resistance to the current targeted-therapy agents G Khamisipour, F Jadidi-Niaragh, AS Jahromi, K Zandi, M Hojjat-Farsangi Tumor Biology 37, 10021-10039, 2016 | 90 | 2016 |
| Berberine: A novel therapeutic strategy for cancer P Samadi, P Sarvarian, E Gholipour, KS Asenjan, L Aghebati‐Maleki, ... IUBMB life 72 (10), 2065-2079, 2020 | 86 | 2020 |
| Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine H Hassannia, M Ghasemi Chaleshtari, F Atyabi, M Nosouhian, A Masjedi, ... Immunology 159 (1), 75-87, 2020 | 81 | 2020 |
| Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells M Hojjat-Farsangi, F Ghaemimanesh, AH Daneshmanesh, AA Bayat, ... PloS one 8 (4), e61167, 2013 | 78 | 2013 |
| Oncostatin M: A mysterious cytokine in cancers A Masjedi, F Hajizadeh, FB Dargani, B Beyzai, M Aksoun, ... International Immunopharmacology 90, 107158, 2021 | 76 | 2021 |
| Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway A Masjedi, H Hassannia, F Atyabi, A Rastegari, M Hojjat-Farsangi, ... International journal of biological macromolecules 133, 436-445, 2019 | 74 | 2019 |
| The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells M Hojjat-Farsangi, AS Khan, AH Daneshmanesh, A Moshfegh, Å Sandin, ... PloS one 8 (10), e78339, 2013 | 73 | 2013 |
Mehdi YousefiTabriz University of Medical SciencesVerified email at tbzmed.ac.ir
